Crescent Biopharma, Inc. (CBIO)
Market Open
8 Dec, 19:58
NASDAQ (CM) NASDAQ (CM) Primary 
LSE $
13. 30
+0.23
+1.76%
$
198.25M Market Cap
- P/E Ratio
- Div Yield
71,944 Volume
- Eps
$ 13.07
Previous Close Day Range
12.86 13.31
Year Range
9.81 37
Want to track CBIO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Crescent Biopharma: Chasing The Summit Hype
Crescent Biopharma is an early-stage biotech with a promising PD-1/VEGF bispecific antibody, aiming for first-in-human trials in late 2025. The company is well-funded, with over $150 million in cash and a manageable burn rate, supporting operations for 2–3 years. Risks include being behind competitors and the unproven clinical potential of their lead candidate, but sector hype remains strong.
Seekingalpha | 3 months ago
2025 © Marketlog. All Rights Reserved.
